Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) EPS (Basic) (2017 - 2025)

Sutro Biopharma (STRO) has disclosed EPS (Basic) for 9 consecutive years, with -$20.78 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 23.97% to -$20.78 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.5 through Dec 2025, up 22.68% year-over-year, with the annual reading at -$22.49 for FY2025, 23.5% up from the prior year.
  • EPS (Basic) hit -$20.78 in Q4 2025 for Sutro Biopharma, down from -$0.67 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.52 in Q4 2023 to a low of -$27.33 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$2.9 across 5 years, with a median of -$0.65 in 2021.
  • Biggest five-year swings in EPS (Basic): skyrocketed 185.25% in 2023 and later tumbled 5355.77% in 2024.
  • Year by year, EPS (Basic) stood at -$0.83 in 2021, then increased by 26.51% to -$0.61 in 2022, then surged by 185.25% to $0.52 in 2023, then tumbled by 5355.77% to -$27.33 in 2024, then rose by 23.97% to -$20.78 in 2025.
  • Business Quant data shows EPS (Basic) for STRO at -$20.78 in Q4 2025, -$0.67 in Q3 2025, and -$0.14 in Q2 2025.